Genomics — US PTAB Patent Cases
7 decisions indexed
Page 1 of 1 · 7 total
Tempus AI, Inc. v.Guardant Health Inc.
Guardant Health’s ’699 patent on duplex consensus sequencing is challenged by Tempus AI, which alleges the claims are obvious over earlier academic publications. The petition seeks institution of an IPR and cancellation of claims 1‑27.
Tempus AI, Inc. v.Guardant Health Inc.
Tempus AI seeks to invalidate Guardant Health’s 30‑claim DNA‑sequencing patent, arguing the claims are obvious over Kinde, Craig, and NEB Expressions. The petition requests institution of the IPR.
Tempus AI, Inc. v.Guardant Health Inc.
Tempus AI petitions to invalidate Guardant Health’s ’699 patent, asserting that all 27 claims are obvious over Kinde and Miner. The petition emphasizes claim constructions that broaden the scope to circulating cellular DNA and argues discretionary denial is improper.
Tempus AI, Inc. v.Guardant Health Inc.
Tempus AI seeks to invalidate all 30 claims of Guardant Health’s DNA‑sequencing patent, arguing they are obvious over Kinde, Craig, and NEB Expressions. The petition asserts no claim construction is needed and that discretionary denial is inappropriate.
Illumina, Inc. v.Molecular Loop Biosciences, Inc.
Illumina has filed an IPR petition seeking to invalidate all nine claims of Molecular Loop’s ’730 DNA‑sequencing patent, arguing that the Chee patent and a combination of other references anticipate or render obvious each claim. The petition also urges the Board not to deny institution under §§ 325(d) and 314(a).
Integrated DNA Technologies, Inc. et al. v.Tecan Group AG
IDT has filed an IPR petition challenging Tecan’s ’108 NGS library‑preparation patent, asserting that the Meyer publication anticipates most claims and that the remaining claims are obvious. The petition also argues against discretionary denial.
Tempus AI, Inc. v.Guardant Health Inc.
Tempus AI has filed an IPR petition challenging Guardant Health’s ’306 patent covering cfDNA sequencing methods. The challenger asserts that all claim elements were disclosed in earlier publications such as Bielas and Vogelstein, rendering the claims obvious. The petition seeks institution of review to invalidate the patent.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.